News articles about Cascadian Therapeutics (NASDAQ:CASC) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cascadian Therapeutics earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.9419204266223 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Shares of CASC stock opened at $10.02 on Friday. The firm has a market cap of $506.61, a price-to-earnings ratio of -7.48 and a beta of 3.79. Cascadian Therapeutics has a 52-week low of $3.18 and a 52-week high of $10.21.
Several research analysts have commented on the stock. ValuEngine raised shares of Cascadian Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 31st. BidaskClub raised shares of Cascadian Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Wednesday, January 31st. Raymond James Financial downgraded shares of Cascadian Therapeutics from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 31st. Zacks Investment Research downgraded shares of Cascadian Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Finally, Cantor Fitzgerald set a $10.00 price target on shares of Cascadian Therapeutics and gave the company a “hold” rating in a report on Friday, March 9th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. Cascadian Therapeutics currently has an average rating of “Hold” and a consensus price target of $6.17.
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.